论文部分内容阅读
目的检测蛋白激酶B(PKB)在卵巢上皮性癌组织中的表达,探讨其作用机制及临床意义。方法应用逆转录-聚合酶链反应技术(RT-PCR)和western印迹方法对2000年1月至2006年12月在中国医科大学附属第一医院、中国医科大学附属盛京医院、辽宁省肿瘤医院行手术治疗,经病理组织学检查确诊的50例卵巢上皮性癌组织,正常卵巢组织15例,卵巢瘤样病变10例,卵巢良性肿瘤10例,交界性肿瘤10例的PKB的表达进行了分析。结果PKBmRNA在卵巢上皮性癌组织中的半定量检测结果为0.669±0.093,与正常卵巢、卵巢瘤样病变及卵巢良性肿瘤相比,差异无统计学意义(P>0.05);western印迹检测见卵巢上皮性癌组织中磷酸化PKB蛋白(0.496±0.033)与正常卵巢(0.109±0.028)、卵巢瘤样病变(0.121±0.035)及卵巢良性肿瘤组织(0.118±0.023),量化后比较差异有统计学意义(P<0.05),且在Ⅲ～Ⅳ期卵巢癌中的表达水平明显高于Ⅰ～Ⅱ期。结论磷酸化PKB蛋白与卵巢上皮性癌的发生、发展、浸润呈正相关,有望成为卵巢上皮性癌生物学行为的重要指标。
Objective To detect the expression of protein kinase B (PKB) in epithelial ovarian cancer and to explore its mechanism of action and its clinical significance. Methods From January 2000 to December 2006, the First Affiliated Hospital of China Medical University, the Shengjing Hospital Affiliated to China Medical University, Liaoning Provincial Tumor Hospital Fifty cases of epithelial ovarian cancer, 15 cases of normal ovarian tissue, 10 cases of ovarian neoplasia, 10 cases of ovarian benign tumor and 10 cases of borderline tumor were analyzed by pathological examination. . Results The semi-quantitative detection of PKB mRNA in epithelial ovarian cancer was 0.669 ± 0.093, which was not significantly different from that of normal ovarian tumor and ovarian benign tumor (P> 0.05) There were statistically significant differences between the phosphorylated PKB protein (0.496 ± 0.033) and normal ovary (0.109 ± 0.028), ovarian neoplasia (0.121 ± 0.035) and benign ovarian tumor (0.118 ± 0.023) in epithelial carcinoma (P <0.05), and the expression levels in stage Ⅲ ~ Ⅳ ovarian cancer were significantly higher than those in stage Ⅰ ~ Ⅱ. Conclusions Phosphorylated PKB protein is positively correlated with the occurrence, development and infiltration of epithelial ovarian cancer, which may be an important index of the biological behavior of epithelial ovarian cancer.